Evidence map›Paper›PMID 26727971›Full record

ArticlePediatric blood & cancer2016

Successful Treatment of Genetically Profiled Pediatric Extranodal NK/T-Cell Lymphoma Targeting Oncogenic STAT3 Mutation.

Troy A McEachron, Ivan Kirov, Minkkwan Wungwattana, Daisy Cortes, Keri B Zabokrtsky, Aaron Sassoon, David Craig, John D Carpten, Leonard S Sender

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric blood & cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Extranodal NK/T cell lymphoma.Blood research · 2020
    Review
  5. Current treatment approaches for NK/T-cell lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Troy A McEachronIntegrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, Arizona.
Ivan KirovDivision of Oncology, Hyundai Cancer Institute, Children's Hospital of Orange County, Orange, California.
Minkkwan WungwattanaPediatric Hematology/Oncology Residency Program, School of Medicine, University of California-Irvine/Children's Hospital of Orange County, Orange, California.
Daisy CortesPediatric Hematology/Oncology Fellowship Program, School of Medicine, University of California-Irvine/Children's Hospital of Orange County, Orange, California.
Keri B ZabokrtskyHyundai Cancer Genomics Center, Children's Hospital of Orange County, Orange, California.
Aaron SassoonDepartment of Pathology, Children's Hospital of Orange County, Orange, California.
David CraigNeurogenomics Division, Translational Genomics Research Institute, Phoenix, Arizona.
John D CarptenIntegrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, Arizona.
Leonard S SenderHyundai Cancer Genomics Center, Children's Hospital of Orange County, Orange, California.
Children's Hospital of Orange County · USTranslational Genomics Research Institute · USUniversity of California, Irvine · USUniversity of California, Irvine Medical Center · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

Extranodal natural killer (NK)/T-cell lymphoma (ENKTCL) is a distinct type of non-Hodgkin lymphoma predominantly observed in Asian and Latin American adult males. A 12-year-old Hispanic female diagnosed with ENKTCL was enrolled in our genomic profiling research protocol. We identified specific somatic alterations consistent with diagnosis of ENKTCL as well as oncogenic mutations in MAP2K1 and STAT3. To our knowledge, this is the first report of an immunophenotypically confirmed and genetically profiled case of ENKTCL in a female pediatric patient in the United States, including its unique treatment and favorable outcome.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsAsparaginaseChemoradiotherapyChildCytarabineDexamethasoneDNA Mutational AnalysisEtoposideFemaleHumansHydrocortisoneHydroxamic AcidsIfosfamideLymphoma, Extranodal NK-T-CellMAP Kinase Kinase 1MethotrexateAsparaginaseCytarabineDexamethasoneEtoposideHydrocortisoneHydroxamic AcidsIfosfamideMAP2K1 protein, humanMAP Kinase Kinase 1MethotrexatePositive Regulatory Domain I-Binding Factor 1PRDM1 protein, humanRepressor ProteinsSTAT3 protein, humanSTAT3 Transcription FactorVorinostatextranodal NK/T-cell lymphomagenomeSTAT3

Identifiers

PMID26727971
PMCPMC7510171
OpenAlexW2230446255

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.